t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Brain Research

• Publication date

  2014-05-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.brainres.2014.03.027PMID 24675027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway.

  2013cited by this paper
• Improved method for the preparation of a human cell-based, contact model of the blood-brain barrier.

  2013cited by this paper
• The transcriptome of cerebral ischemia.

  2012cited by this paper
• A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.

  2012cited by this paper
• Acute neuronal injury and blood genomic profiles in a nonhuman primate model for ischemic stroke.

  2012cited by this paper
• t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.

  2012influential reference
• A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.

  2012cited by this paper
• Desmoteplase: discovery, insights and opportunities for ischaemic stroke

  2012cited by this paper
• Tissue-Type Plasminogen Activator Regulates the Neuronal Uptake of Glucose in the Ischemic Brain

  2012cited by this paper
• Tissue-Type Plasminogen Activator has a Neuroprotective Effect in the Ischemic Brain Mediated by Neuronal TNF-α

  2012cited by this paper
• The Desmoteplase in Acute Ischemic Stroke (DIAS) Clinical Trial Program

  2012cited by this paper
• Annexin A2 Promotes Glioma Cell Invasion and Tumor Progression

  2011cited by this paper
• The plasmin–antiplasmin system: structural and functional aspects

  2011cited by this paper
• Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

  2010cited by this paper
• Plasmin on adherent cells: from microvesiculation to apoptosis.

  2010cited by this paper
• A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.

  2009cited by this paper
• Recombinant Tissue Plasminogen Activator Increases Blood-Brain Barrier Disruption in Acute Ischemic Stroke: An MR Imaging Permeability Study

  2009cited by this paper
• Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

  2008cited by this paper
• Thrombolytic Toxicity: Blood Brain Barrier Disruption in Human Ischemic Stroke

  2008cited by this paper
• Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

  2008cited by this paper
• Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain.

  2008cited by this paper
• Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid.

  2008influential reference
• Recombinant Desmodus rotundus Salivary Plasminogen Activator Crosses the Blood–Brain Barrier Through a Low-Density Lipoprotein Receptor-Related Protein-Dependent Mechanism Without Exerting Neurotoxic Effects

  2007cited by this paper
• Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit.

  2007cited by this paper
• Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes

  2006cited by this paper
• The Urokinase/PAI-2 Complex

  2006cited by this paper
• Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity.

  2006cited by this paper
• Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Inhibits Tissue-Type Plasminogen Activator-Induced Potentiation of Excitotoxic Injury

  2005cited by this paper
• In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone.

  2004cited by this paper
• Cleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity

  2004cited by this paper
• Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin

  2004cited by this paper
• Blood-Brain Barrier Damage Induces Release of α2-Macroglobulin*

  2003cited by this paper
• Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator

  2003cited by this paper
• Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

  2003cited by this paper
• Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.

  1999cited by this paper
• Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice

  1998cited by this paper
• Perturbation of the integrity of the blood‐brain barrier by fibrinolytic enzymes

  1998cited by this paper
• Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway.

  1998cited by this paper
• Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator

  1995cited by this paper
• Protease nexin-1 and thrombin modulate neuronal Ca2+ homeostasis and sensitivity to glucose deprivation-induced injury

  1995cited by this paper
• Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators (*)

  1995cited by this paper
• Contraction of human brain endothelial cells induced by thrombogenic and fibrinolytic factors. An in vitro cell culture model.

  1995cited by this paper
• Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer.

  1994cited by this paper
• The prolonged presence of glia-derived nexin, an endogenous protease inhibitor, in the hippocampus after ischemia-induced delayed neuronal death.

  1992cited by this paper
• Establishment of a line of human fetal glial cells that supports JC virus multiplication.

  1985cited by this paper
• OTENTIATING EFFECT OF ENDOTHELIAL CELLS ON ASTROCYTIC LASMINOGEN ACTIVATOR INHIBITOR TYPE-1 GENE EXPRESSION N AN IN VITRO MODEL OF THE BLOOD – BRAIN BARRIER

  year unknowncited by this paper

• Fibrin Selective Alteplase with Improved Thrombolysis and Inhibition Resistance Engineered by Rational Design

  2026influential citation
• The End of Tissue-Type Plasminogen Activator’s Reign?

  2022cites this paper
• Corneal and scleral permeability of Desmoteplase in different species.

  2020cites this paper
• Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement

  2020cites this paper
• Evaluation of long-term rt-PA effects on bEnd.3 endothelial cells under ischemic conditions; changes in ZO-1 expression and glycosylation of the bradykinin B2 receptor.

  2020cites this paper
• Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord

  2019cites this paper
• Tissue Plasminogen Activator and MRI Signs of Cerebral Small Vessel Disease

  2019cites this paper
• Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide

  2019cites this paper
• Fibrinolytic Capacity of Desmoteplase Compared to Tissue Plasminogen Activator in Rabbit Eyes

  2019cites this paper
• Deficiency of Bmal1 disrupts the diurnal rhythm of haemostasis

  2019cites this paper
• Tissue-type plasminogen activator and MRI features of cerebral small vessel disease

  2018cites this paper
• [Thrombolytic therapy of ischemic stroke].

  2018cites this paper
• In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain

  2018cites this paper
• Vascular Degeneration in Human Parkinson Disease: Novel Insights in the Pathologies, Functions and Mechanisms

  2017cites this paper
• Bivard, A. et al. (2017) Impact of computed tomography perfusion imaging on the response to tenecteplase in ischemic stroke: analysis of two

  2016cites this paper
• Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke

  2016cites this paper
• Recombinant tissue plasminogen activator enhances microparticle release from mouse brain-derived endothelial cells through plasmin.

  2016cites this paper
• Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities

  2016cites this paper
• Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials

  2016cites this paper
• Progress in Intravenous Thrombolytic Therapy for Acute Stroke.

  2015cites this paper
• Alterations of the Blood-Brain Barrier in Post-Traumatic Epilepsy

  2015cites this paper
• Pharmacological therapy of acute ischaemic stroke: Achievements and problems.

  2015cites this paper
• Blood–brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics

  2015cites this paper
• String Vessel Formation is Increased in the Brain of Parkinson Disease

  2015cites this paper
• Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system

  2015cites this paper
• Altered Behavior in Mice with Deletion of the Alpha2-Antiplasmin Gene

  2014cites this paper